SOUTH
SAN FRANCISCO, Calif., Nov. 1, 2022
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
synthetic lethality focused precision medicine oncology company
committed to the discovery and development of targeted
therapeutics, announced its participation in investor conferences
in November 2022 and its plans to
host an Investor R&D Day in December
2022.
Jefferies London Healthcare Conference
Tuesday, November 15th,
2022 at 5:00pm GMT // 12:00pm ET
- Fireside chat with Yujiro Hata,
Chief Executive Officer, IDEAYA Biosciences, hosted by Maury
Raycroft Ph.D. Equity Research Analyst
Stifel Healthcare Conference
Wednesday, November 16, 2022 at
8:00am ET
- Fireside chat with Paul Stone,
Chief Financial Officer, IDEAYA Biosciences, hosted by Ben Burnett, Ph.D. Vice President, Equity
Analyst
IDEAYA Biosciences Investor R&D Day
Monday, December 12, 2022 at
8:00am ET
- IDEAYA will host an Investor R&D Day webcast showcasing
highlights and insights across its clinical and preclinical
pipeline programs, with participation of key opinion leaders
- Pre-registration is available through the following link
https://lifescievents.com/event/ideaya-rd-day/ or alternatively,
through IDEAYA's investor relations events page at
https://ir.ideayabio.com/events
A live audio webcast of conference events, as permitted by
conference host, and of the Investor R&D Day webcast will be
available at the "Investors/News and Events/Investor Calendar"
section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-plans-for-investor-rd-day-and-participation-in-upcoming-investor-conferences-301662966.html
SOURCE IDEAYA Biosciences, Inc.